Trial ID or NCT#



recruiting iconRECRUITING


The primary aim of this trial is to estimate the duration of hepatic progression-free survival (HPFS) in participants treated with bland embolization (BE), transcatheter arterial Lipiodol chemoembolization (TACE), and embolization by drug-eluting beads (DEB). The primary hypothesis is that chemoembolization will be nearly twice as durable as bland embolization; thatis, the hazard ratio for HPFS will be 1.76 or better.

Official Title

Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Nishita Kothary, MD
Nishita Kothary, MD
Interventional radiologist
Professor of Radiology (Interventional Radiology) at the Stanford University Medical Center
Pamela L. Kunz
David S. Wang, MD
David S. Wang, MD
Interventional radiologist, Radiologist
Clinical Assistant Professor, Radiology

Contact us to find out if this trial is right for you.


Risa Jiron
(650) 736-1598